Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01310439 · ClinicalTrials.gov registry record
Attention-Deficit/Hyperactivity Disorder (ADHD) Brain Activity Changes to Psychostimulants
A clinical trial of Attention Deficit Hyperactivity Disorder, sponsored by Hartford Hospital.
- Completed
- Registry status
- 38
- Enrollment target
- 1
- Study location
NCT01310439: Completed study of Attention Deficit Hyperactivity Disorder, sponsored by Hartford Hospital.
NCT01310439 is a study of Attention Deficit Hyperactivity Disorder that has completed, run by Hartford Hospital. The registered enrollment target is 38 participants, below the 216-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01310439, a study of Attention Deficit Hyperactivity Disorder, has completed, sponsored by Hartford Hospital.
- COMPLETED
- Registry status
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine the neural basis of response inhibition, working memory, and sustained attention in adolescents and adults with Attention-Deficit/Hyperactivity Disorder (ADHD), with particular emphasis on quantifying the effects of methylphenidate (i.e., treatment with psychostimulants) on neural function. Participants will undergo electrophysiological measurement of brain function during laboratory cognitive tasks. This research is aimed to develop a better understanding of how ADHD neural dysfunction relates to clinical presentation and medication response during the transition from adolescence to adulthood. The specific aims and hypotheses are: Specific Aim: To characterize the effect of Ritalin (methylphenidate) on neural activity underlying performance on the response inhibition task in ADHD adolescents and adults. Hypothesis 1) Methylphendiate will increase N2 and P3 amplitude in ADHD persons during medicated EEG sessions; Hypothesis 2) There will be a significant age × medication interaction such that ADHD teens will show increased amplitude of N2 while medicated, particularly at frontal sites, whereas ADHD adults will show differentially greater effect of medication on P3 amplitude and latency at central sites. Hypothesis 3) Brain activity assessed by fMRI will differ between unmedicated and medicated states.
Conditions Studied
Study Locations (1)
Connecticut
- Hartford Hospital / The Institute of Living - Hartford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2004-05 |
| Est. Completion | 2010-06 |
What the finished NCT01310439 record still lists
NCT01310439 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 216-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Attention Deficit Hyperactivity Disorder appearing as the primary indexed condition, and to 0 interventions.
NCT01310439 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT01310439 about?
NCT01310439 is a clinical study titled "Attention-Deficit/Hyperactivity Disorder (ADHD) Brain Activity Changes to Psychostimulants". The purpose of this study is to examine the neural basis of response inhibition, working memory, and sustained attention in adolescents and adults with Attention-Deficit/Hyperactivity Disorder (ADHD), with particular emphasis on quantifying the effects of methylphenidate (i.e., treatment with psycho...
What is the current status of trial NCT01310439?
This trial is currently completed. The enrollment target is 38 participants. The study started on 2004-05. Estimated completion is 2010-06.
What conditions does trial NCT01310439 study?
This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder.
Who is sponsoring clinical trial NCT01310439?
This trial is sponsored by Hartford Hospital, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01310439 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit Hyperactivity Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01310439's enrollment target sits among peer trials
38 72nd of 102 higher than 29 of 102 other Attention Deficit Hyperactivity Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Attention Deficit Hyperactivity Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Developing Brain, Impulsivity and Compulsivity
RECRUITING
-
HOPS Study: A Conceptual Replication
RECRUITING · NA
-
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
RECRUITING · Phase 4
-
COMT Inhibition Among Individuals With Comorbid AUD/ADHD
RECRUITING · Phase 2
-
Acute Effects of Exercise in College Students With ADHD
RECRUITING · NA
-
Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia